Latest News & Updates

FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer
October 15, 2021

Continue Reading »

FDA approves pembrolizumab combination for the first-line treatment of cervical cancer
October 13, 2021

Continue Reading »

FDA approves abemaciclib with endocrine therapy for early breast cancer
October 13, 2021

Continue Reading »

FDA recognizes Memorial Sloan-Kettering database of molecular tumor marker information
October 8, 2021

Continue Reading »

FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer
October 15, 2021

Continue Reading »

FDA approves pembrolizumab combination for the first-line treatment of cervical cancer
October 13, 2021

Continue Reading »

FDA approves abemaciclib with endocrine therapy for early breast cancer
October 13, 2021

Continue Reading »

FDA recognizes Memorial Sloan-Kettering database of molecular tumor marker information
October 8, 2021

Continue Reading »

Get More from FLASCO With Your Membership

The Corporate Membership Program allows FLASCO to expand our offerings to our membership. Every FLASCO meeting also provides the industry representative with opportunities to educate our members. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.

Corporate Members:

Diamond Elite

Diamond

Platinum

Gold

We're Here to Help Contact Us

Contact Us

Add your name, email & message below: